Location: Virtual
Exploring applications for therapeutic trials and clinical use
The development of blood biomarkers that reflect Alzheimer’s disease (AD) pathophysiology has offered potential as scalable tests for dementia differential diagnosis and early detection. Blood phosphorylated tau (p-tau) is elevated across the AD continuum. In primary and secondary care, p-tau provides evidence of underlying AD pathology which can be informative in the differential diagnosis of dementia and patient management. Preclinically, p-tau highlights dementia risk, aids strategies in therapeutic trial recruitment and potentially outcome measures.
In this webcast, recent data will demonstrate the ability of p-tau and other blood biomarkers to detect the accumulation of amyloid pathology in asymptomatic individuals. Further, in the symptomatic phase, data will show the capability of p-tau biomarkers (including different epitopes and analytical platforms) to detect AD pathology in a heterogenous memory clinic population – which are comparable to clinically validated cerebrospinal fluid (CSF) tests.
You will learn:
- How easily accessible blood tests can help to identify early amyloid pathology in asymptomatic individuals or in a heterogeneous population with cognitive complaints
- How phosphorylated tau relates to AD pathology
- What different epitopes of p-tau are promising as blood-based AD biomarkers
Speaker: Dr. Nicholas Ashton, Asst. Professor of Neurochemistry, University of Gothenburg
Related Posts
Accelerate Building Custom Spatial Proteomic Panels for New Biological Insights
Ultrasensitive Neuroimmune Biomarker Measurement for Translational Research and Therapeutic Development
Underdiagnosis of Alzheimer’s disease pathology in patients with cardiovascular disease
Decoding Neurodegeneration: High-plex Spatial Proteomics Reveal Distinct Cell Phenotypes and Pathological Signatures in Parkinson’s and Alzheimer’s Disease
In this webinar, Dr. Birgitt Schuele, Associate Professor (Research) of Pathology at Stanford University, showcases how ultrahigh-plex spatial proteomics is being used to uncover distinct cell phenotypes and pathological signatures…
Understanding the Brain: Advancing Neurodegeneration Research with Ultrahigh-Plex Spatial Proteomics
In this webinar, learn how ultrahigh-plex spatial phenotyping has been applied to neurodegenerative disease research.
p-Tau 205 and p-Tau 212: Emerging Biomarkers for Alzheimer’s Disease Research
Spatial Awareness: AI-powered Profiling of Trillions of Immune Cell Distribution Data Points Reveals Key Predictors of Cancer Recurrence Risk
This webinar highlights a groundbreaking study recently published as a Nature cover story (April 2025). Dr. Joe Yeong will describe how a pre-designed analytical framework—driven by well-defined clinical and scientific…
Multimodal Single-Cell Spatial Transcriptomics and Proteomics to Uncover the Biological Processes Driving Immunotherapy Response and Resistance in Renal Cancer
In this webinar, Dr. Anne-Laure Cattin from the Cancer Dynamics Laboratory at The Francis Crick Institute in London, will share her research on kidney cancer, focusing on the integration of…